Skip to main content

Table 3 Clinicopathologic characteristics of HER2 status-HERmark concordant and discordant groups

From: Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival

 

Concordant negative

Concordant positive

Discordant low

Discordant high

 

HER2 -, H2T low

HER2 +, H2T high

HER2 +, H2T low

HER2 -, H2T high

Parameter

No.

%

No.

%

No.

%

No.

%

Tumor size (cm)

        

  <2

45

51%

30

49%

9

47%

6

43%

  >2

43

49%

31

51%

10

53%

8

57%

Tumor grade

        

  Grade 1 and Grade 2

41

54%

10

19%*

6

40%

8

62%

  Grade 3

35

46%

43

81%

9

60%

5

38%

Stage at initial diagnosis

        

  I and II

73

83%

40

65%

14

74%

8

47%

  III and IV

15

17%

22

35%*

5

26%

9

53%

Nodal status at diagnosis

        

  Node negative

40

55%

15

28%

7

47%

3

25%

  Node positive

33

45%

38

72%

8

53%

9

75%

Hormone receptor (ER/PR) status

        

  Negative

19

21%

23

37%*

6

32%

4

24%

  Positive

72

79%

40

63%*

13

68%

13

76%

  1. * P <0.05. Fisher exact test was performed for each parameter between two concordant groups, or, between two discordant groups. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; H2T, quantitative total HER2 expression by HERmark; PR, progesterone receptor.